News

Ares Genetics Advances AI-powered Infectious Disease and Antibiotic Resistance Test

Ares Genetics to start EUR 1.3 million TRIPLE-A development project co-funded by Vienna Business Agency, and initiates set-up of R&D and service…

Read more

Valneva Announces its Intention to Delist from the Vienna Stock Exchange

Valneva announced that it intends to delist from the Vienna Stock Exchange (VSE) in order to focus on the best capital markets for life science…

Read more

University of Vienna and Medical University of Vienna extend successful collaboration with Max F. Perutz Laboratories

The University of Vienna and Medical University of Vienna are extending their successful collaboration with Max F. Perutz Laboratories. Rectors Heinz…

Read more

HOOKIPA Achieves First Research Milestone in HIV Collaboration and License Agreement with Gilead

The agreement grants Gilead exclusive rights to HOOKIPA’s TheraT® and VaxWave® investigational arenavirus-based immunization technologies for the…

Read more

Valneva Awarded FDA Fast Track Designation for Chikungunya Vaccine Candidate

Valneva announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its chikungunya vaccine candidate, VLA1553. …

Read more

New Managing Director at VBCF

In January 2019, the new Managing Director of the Vienna BioCenter Core Facilities GmbH, Daniele Soroldoni, has started his work. Welcome!

Read more

VBC Summer School 2019 application deadline: 31 January 2019

The Vienna Biocenter Summer School provides a unique opportunity for approx. 28 undergraduate students to work side-by-side with leading researchers…

Read more

Ares Genetics Teams Up with Leading Global Pharma Company in Fight Against Antibiotic Resistance

Strategic collaboration agreement with Sandoz to develop digital anti-infectives platform.

Read more

Valneva Initiates Phase 2 Clinical Development For Its Lyme Disease Vaccine Candidate

Valneva today announced the initiation of the Phase 2 Clinical Development for its leading, unique Lyme disease vaccine candidate VLA15.

Read more

HOOKIPA Doses First Patient in a Phase 2 Clinical Trial of Prophylactic Vaccine Candidate HB-101 against Cytomegalovirus

The clinical trial will be conducted at approximately 35 centers worldwide and will include a total of 150 male and female patients.

Read more

Large infrastructure project PHENOPlant for phenotyping of crop plants approved

Congrats to the VBCF Plant Sciences Facility! Their FFG FuE Infrastrukturförderung application for a multi-sensor and multi-approach high-throughput…

Read more